Introduction to Mammalian Genome Special Issue: Inflammation and Immunity in Cancer

Overview

Journal Mamm Genome

Specialty Genetics

Date 2018 Nov 4

PMID 30390107

Authors

Andreas Behren

Daniel Speidel

George Kollias

Viive M Howell

Affiliations

Soon will be listed here.

References

Ginn S, McCormack M, Alexander I . Thymocyte self-renewal and oncogenic risk in immunodeficient mouse models: relevance for human gene therapy clinical trials targeting haematopoietic stem cell populations?. Mamm Genome. 2018; 29(11-12):771-776. DOI: 10.1007/s00335-018-9780-5. View

Hayes S, Clarke S, Pavlakis N, Howell V . The role of proteomics in the age of immunotherapies. Mamm Genome. 2018; 29(11-12):757-769. DOI: 10.1007/s00335-018-9763-6. View

Lim S, Rizos H . Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms. Mamm Genome. 2018; 29(11-12):866-878. PMC: 6267680. DOI: 10.1007/s00335-018-9757-4. View

Guillerey C . Roles of cytotoxic and helper innate lymphoid cells in cancer. Mamm Genome. 2018; 29(11-12):777-789. DOI: 10.1007/s00335-018-9781-4. View

Cho A, McKelvey K, Lee A, Hudson A . The intertwined fates of inflammation and coagulation in glioma. Mamm Genome. 2018; 29(11-12):806-816. DOI: 10.1007/s00335-018-9761-8. View

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

Perera A, Sajnani K, Dickinson J, Eri R, Korner H . NLRP3 inflammasome in colitis and colitis-associated colorectal cancer. Mamm Genome. 2018; 29(11-12):817-830. DOI: 10.1007/s00335-018-9783-2. View

Peel E, Belov K . Lessons learnt from the Tasmanian devil facial tumour regarding immune function in cancer. Mamm Genome. 2018; 29(11-12):731-738. DOI: 10.1007/s00335-018-9782-3. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

10.

Kazantseva M, Mehta S, Eiholzer R, Hung N, Wiles A, Slatter T . A mouse model of the Δ133p53 isoform: roles in cancer progression and inflammation. Mamm Genome. 2018; 29(11-12):831-842. DOI: 10.1007/s00335-018-9758-3. View

11.

Stamm H, Wellbrock J, Fiedler W . Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer. Mamm Genome. 2018; 29(11-12):694-702. DOI: 10.1007/s00335-018-9770-7. View

12.

Gowrishankar K, Birtwistle L, Micklethwaite K . Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells. Mamm Genome. 2018; 29(11-12):739-756. DOI: 10.1007/s00335-018-9756-5. View

13.

McKelvey K, Hudson A, Back M, Eade T, Diakos C . Radiation, inflammation and the immune response in cancer. Mamm Genome. 2018; 29(11-12):843-865. PMC: 6267675. DOI: 10.1007/s00335-018-9777-0. View

14.

Hutchison S, Pritchard A . Identifying neoantigens for use in immunotherapy. Mamm Genome. 2018; 29(11-12):714-730. PMC: 6267674. DOI: 10.1007/s00335-018-9771-6. View

15.

Duarte J, Peyper J, Blackburn J . B cells and antibody production in melanoma. Mamm Genome. 2018; 29(11-12):790-805. DOI: 10.1007/s00335-018-9778-z. View

16.

Cebon J . Perspective: cancer vaccines in the era of immune checkpoint blockade. Mamm Genome. 2018; 29(11-12):703-713. PMC: 6267701. DOI: 10.1007/s00335-018-9786-z. View